CDK6 and lung cancer: Furthermore, the combined application of miR-506 and miR-143 in the treatment of lung cancer LC and PC synergistically downregulates CDK1, CDK4, and CDK6, blocking both the G1/S and G2/M transitions and inducing robust apoptotic activity (71).